Adam Gridley, MBA

Executive Chairman

Adam is currently CEO of Allay Therapeutics. He was previously the CEO at Entera Bio, a biotechnology company specializing in the oral delivery of large molecules and biologics. And before that, he was President, CEO, and Director of Histogenics, a cell therapy and biologics company developing novel therapeutics for cartilage defects, and helped the company complete a successful $70 million IPO, raised over $130 million, recruited a new management team, and helped lead several successful clinical and manufacturing initiatives for the Company’s Phase 3 trial of NeoCart. In addition, he completed licensing transactions with Intrexon, MEDINET (Japan), and most recently a reverse merger with Ocugen Inc. Prior to Histogenics, Adam was Senior Vice President, Technical Operations/Global Site Head at Merz Pharma, one of the world’s largest aesthetics companies. He was previously Senior Vice President of Corporate Development at BioForm Medical, where he played a key role in BioForm’s IPO, several acquisitions and product launches, and ultimately the sale of BioForm to Merz. Adam was previously on the Board of Directors of the Alliance for Regenerative Medicine (ARM), and is on the Board of Advisors for Life Science Cares, a nonprofit organization leveraging the collective impact of the Boston life sciences industry to address poverty in the Boston area. Adam holds a BS and MBA from the University of Denver.